Gracell Biotechnologies Inc.

Stock market turmoil due to macroeconomic uncertainty and biopharmaceutical industry-specific concerns have made it more difficult for publicly traded drug developers to pursue follow-on public offeri

AstraZeneca already considers China one of its most important markets and is increasing its focus there, announcing a $2.5bn research and development investment in Beijing along with three partnership

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

BioNTech’s close to $1bn acquisition of Biotheus announced earlier this month marked another big M&A deal between a Chinese biotech and a foreign firm following AstraZeneca’s roughly $1.2bn buyou